Novartis enters an agreement to license an mRNA-based therapy from China’s Abogen Biosciences, with the total value reported at up to $7.8 billion. Sources say Novartis makes a $575 million upfront payment in exchange for access to Abogen’s RNA technology and an option related to its lead program.

Abogen is advancing ABO-2203, described by outlets as a potential autoimmune treatment. The deal structure, as reported across outlets, includes up to $7.2 billion in additional milestone payments tied to key events in clinical development, regulatory approvals, and commercial performance. One outlet also frames Abogen’s lead drug as having the potential to transform the treatment landscape for patients with autoimmune diseases, while others focus more on deal size and licensing terms.

The coverage broadly agrees on the company names, the mRNA/autoimmune focus of the licensed program, and the reported payment schedule. Differences are mainly in emphasis—some highlight the technology and option rights, while others stress the potential clinical significance of ABO-2203.